Current Report Filing (8-k)
January 13 2020 - 1:22PM
Edgar (US Regulatory)
0001109354
false
0001109354
2020-01-12
2020-01-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2020
BRUKER CORPORATION
(Exact name of registrant as
specified in its charter)
Delaware
|
|
000-30833
|
|
04-3110160
|
(State
or other jurisdiction of
|
|
Commission
File No.
|
|
(I.R.S.
Employer
|
Incorporation or
organization)
|
|
|
|
Identification
No.)
|
40
Manning Road
Billerica,
MA 01821
(Address
of principal executive offices) (Zip Code)
(978) 663-3660
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following
provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which Registered
|
Common Stock, $0.01 par value per share
|
|
BRKR
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On January 13, 2020, during the scheduled
presentation at the 38th Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) will state that
it expects fiscal year 2019 organic revenue growth to be at or near the high end of the Company’s prior organic growth guidance
range.
Because the Company’s financial statements
for the fiscal year ended December 31, 2019 have not yet been finalized or audited, the preliminary statement regarding the Company’s
expectations regarding its fiscal year 2019 organic revenue growth included in this Item 2.02 is subject to change, and the Company’s
actual organic revenue growth for this period may differ materially from this preliminary estimate. Accordingly, you should not
place undue reliance on this preliminary estimate.
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 2.02 of
this Current Report is incorporated into this Item 7.01 by reference.
The information furnished in Item 2.02 and
Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Forward Looking Statements
Any statements contained in this Current Report on Form 8-K
that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management’s
expectations regarding our fiscal year 2019 performance, including our organic revenue growth. Any forward-looking statements contained
herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ
materially from those indicated, including, but not limited to, risks and uncertainties relating to the preliminary nature of the
Company’s fiscal year 2019 financial information, which is subject to completion of the Company’s year-end-audit, and
other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other
factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report
on Form 10-K for the year ended December 31, 2018. We expressly disclaim any intent or obligation to update these forward-looking
statements other than as required by law.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRUKER CORPORATION
(Registrant)
|
|
|
Date: January 13, 2020
|
By:
|
/s/GERALD N. HERMAN
|
|
|
Gerald N. Herman
|
|
|
Chief Financial Officer
|
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024